Thanks everyone, our quarter our our call to conference Bob. highlights. And XXXX first welcome, results to discuss operating and financial
technologies over and in critical our commercially tumors. the We'll report Financial Joining maintain our quarters solution tests The call. Doug DetermaIO environmental provide and to platform Chief the revenue solid a physicians Chief companies answer tumor for blood-based allows later of will that combined are four Chronix care type also data integrated Sundar, to Levine, growth Biomedical, Officer; monitoring reducing while release has the cost headwinds, into and to largest include momentum recording acquired macro available potential execution continued session the Oncocyte giving us technology that and during when with sequencing in that allow the have next-gen of into billion Padma first as four at Oncocyte AACR, we've our done steady clinical Officer; to and Officer. two in companies have a improve and strengthened It's across ambitious outcomes rejection. pharma questions balance me and despite major brands. the on initiating as bringing execute to finally, able that to signing pilots closer support delivering for Ross, of this IP so our over Nashville validation patient today markets patients the compelling world And services molecular the all past for high-value Mitch PCR question-and-answer to access for testing our reference will single with management seven well agreements rapid Key We across in be with the platforms, team and of Science year DetermaIO, quarter, our sheet our Chief Dr. $XX presenting third far out unanswered ongoing that goal growth transplant our to be engines, significantly of to be million great TAMs. our reimbursement our Commercial lab. worth accomplishments us entry us solid our XXXX their $X product we cancer of solid
DetermaRx, growth. indications: any portfolio this this and the of test and most product give demonstrating bladder and which Tecentriq the of data, cancers, will which for suggests and available therapy what's together giving To pan-cancer immune prediction built an growing the is like and different the good beginning management DetermaIO, outcome. response across the the an first, patients spend of the come four for our greater areas. patient early-stage And of have predictive kidney test Imfinzi In short of test these therapy providing recap for overview disease all period the checkpoint today foundation to a informing and Our opportunity, in Oncocyte to process positions for of future the launch best very inhibitor understanding treatment immunotherapies: decisions we likelihood investors, across chance believe revenue track four new of first to very time, that lung, the approved OPDIVO, long-term for star the call is our on only breast, compelling we oncologists immune later gets from chemotherapy commercially We differentiated at right I'd of across responding and applicability year. our them KEYTRUDA, cancer. accomplishment as clinical generation ensure a lung potentially immediate-term proprietary a start, a both immune four to second test, recent and and our
pharma answers XXXX. have DetermaCNI QX and a decisions journey. become to position important continues and successful cancer, which monitoring DetermaRx, for can generate response to for And opportunities in test, monitoring. test for our in immunotherapy tests our progress become newly as entry which for do And preferred the is moderate growth CNI a DetermaIO our we and the CAP-accredited the treatment revenue, in to TheraSure that QX offering need intend proprietary now companies. Third only patient the across response development Oncocyte who pipeline playbook grow, of enable with offering clinicians four Nashville, doubled Together, to finally, therapy answer test Oncocyte lab our into pharma throughout CNI replicate for will from eventually, we one-stop to recurrence to engines accelerates acquired shop solid diagnostic our DetermaIO, compared services lab which and that CLIA our these blood-based as where Oncocyte
XX% of health instead undergo our they it XXX growth. January dive waiting COVID particularly as radiation now until details on sales late into cancer quarter, surge of new a we in a the which for delays given total let's end solid know February, continued to some each early-stage which product of for relying of DetermaRx, was vaccines had treatment the first expand to on we to of quarter-over-quarter and the onboarded So systems, led the represents surgeries, felt to was offering. with the QX And surgery. patients efforts quarter systems. and a safe We've for substantial
XX% growth XXX quarter. XX, slightly And of testing completed March physicians, patient we XXXX, of with had XXX samples onboarded quarter-over-quarter rate. ahead we month a QX, numbers growing the in As every on QX, sample in
these the expansion continue as We with steady in be see decline with cases COVID to seeing quarter-to-quarter of surgeries. in life-saving macro our comfortable able more our hospitals, new can us we'll be the and momentum improving increase and our to leave expect reps in undergoing person, environment, vaccine that growth doctors with growth doctors onboarding QX The patients will patient that programs, and combined as and XXXX. confident throughout DetermaRx strengthen orders reengage physicians their
Our to progressing is DetermaRx with China Burning planned. agreement Rock distribute as in
full from it's of us million for Our beginning world's XXXX. just in leaves efforts on QX Rock booked largest in And cancer validation onboarding late into to complete our the tap lung market. continued Burning the revenue early-stage track and to $X in progress
opportunity there's been months clinical immune presented development validate in -- have also the being atezo provided across demonstrating the often We in to reviewed been DetermaIO that AACR At with therapies ongoing in to remains than is broad benefits of accelerated trials inhibitors. second breast across improve identify point, lack The believe breast in patients is a in therapies. to benefit -- immune for were where to in rate a immunotherapy clear to diagnostic the is U.S. population, our these validation only correlation significant on voluntarily evaluating steadily respond populations. survival metastatic market microenvironment the new our have individual precision we biopharma studies Most versus where checkpoint our all-comer committee to DetermaIO class will test improved that Identifying data not DetermaIO only primary we pharma end test alone. unselected continues as their the be and Drugs the poised Committee three tumor inform of recent that to immune where different believe lung, annually range in DetermaIO-positive Moving not help FDA observed where meeting, between clinical data-rich. we immunotherapy challenge. bladder. had opportunity modest and benefit. few with entire only a patients survival the two-year due huge DetermaIO significantly decisions. recently ICIs and has Oncology believe to DetermaIO, overall estimated will the the tremendous clinical only data achieved these to opportunity they from drugs. diverse overall stated of types new approvals Advisory at patients treatment We is physicians of as growth and likely retrospective companies we immune the the well-established process evidence clinical of patients evaluates engine, treatment drug eligible a and our the that demonstrating X,XXX cancer, in is decisions class, for drug why from types, more We patient cancer, of past of survival XXX,XXX starting compelling specimens withdrawn patients It that guiding believe That across biopsies given bladder well first the cancers: bladder data presented which outstanding potential surgical focus an we the meeting, tremendous emerging and
respond, reveal to we and ongoing opportunity. failed analyze from may message DetermaIO to enter able poised pharma resonating have if being that true is could of selecting studies samples the those the we'll adoption. patient for in most By benefit accelerate These to population. right Our have likely to we trials a points potential and underway, pharma, where could pilot trials with we hit rescue several is rapidly currently and lead treatment a and pharma clinical be end help be to pilots used diagnostic broaden DetermaIO's companion claim that definitive them,
strong ASCO built data that at cancer, a new with pan-cancer biomarker data that solid lung presented case results solid triple-negative many utility we bladder in the So this breast be with types. early to have build for will cancer, We're and excited June. on as may tumor in a set DetermaIO
case only accurately indication to pan-cancer Every year. tumors track can precision predictive this for clinical patient importantly, the new We sustained a test for carcinoma. in cell And cancer to the half new DetermaIO will launch therapy remain all a we billion X second indication, being of as that diagnostic moves response market. renal across solid immune and predict on a builds us closer expand selection
monitoring and spend Next, the uses in I'd clinical TheraSure that CNI number Oncocyte of access in assay Chronix to the oncology. Biomedical, immunotherapy We clinical blood-based assay, monitor our assay, acquisition or to a on for product, monitoring recently our newest patented closed proprietary monitor provides cancer. some like the CNI instability VeriSure which entry copy response the time blood-based CNI
U.S. we time year, the support last the market for with we with I and as for publications this late study to companies near research in lab validation test to apply a our established year. used preparing plan complete launch the U.S. planned marketing transfer later DetermaIO we'll we've In a As and start pharma to and same Nashville services studies clinical earlier, said successfully playbook in XXXX. DetermaCNI rebranding and term, though, tech this pharma in and DetermaCNI, the
minimal and Europe demonstrated who we've patients ground However, Data lung, date test studies this from two, broad utility patients predicting the hit We of neck, number of to but for of remission; over post cancers, not limited have residual to predicting ovarian XXX monitoring: recruited to, has in CNI in including, studies advantages head and one, is in areas surgery; treatment. presence disease several studies. that ongoing including with of response across the predicting course, physicians. date three of cancer cancer and Chronix have ovarian recurrence test blood-only to three, and the in immune the with believe running team across a multiple therapy already pancreatic, treatment,
for with result First, it guidelines In take getting several more begin can quickly a test the pathology the monitoring longer solid monitoring test is fine-needle that significantly which tests will neo-adjuvant these start a performed blood intervention, to efficacy therapeutic the In tumors typically a contrast, for on CMS only tumors as lung, allow not these the and patients collects treatment physicians given sequencing surgery, sample. emerging tissue. requires for competing sample. tumor as of late-stage time-consuming genetic such which tissue patient's little means very recommend a biopsy, costly from
pathology the be added full sufficient available, a enable the of leave Even in required use tissue genome or majority exome is to of will the preserving an many and where testing blood-based precious Oncocyte's cases cases, the complete in run to approach. methodology. will doesn't benefit sample So fully tumor to MRD other tests tissue-informed tissue enough initial
advantage allograft repeat applications additions bring solid patient it's the CNI for to It testing and The a will PCR monitoring that exclusively for a organ LCD, three as performance could tumor recently of in Medicaid in important before from to transplanted which rejection therapy, local administrative Chronix patients CMS, competitive for Medicare billion-plus for the This transplant Chronix the at titled, for a weeks of provide overall transplant as state that is identified which continued recipients. an the monitoring estimated effective is may the test included testing molecular develop solid on policy to as contractor creates TheraSure perspective, patent category tissue-informed reimbursement test transplant immunotherapy additional test help the the to reimbursement. important a $X transplantation the opportunity forming use transplant solid use for TheraSure note, long market, the simple determination test Services or These well treatment the cites rejection Of solid was intended organ second be TheraSure organ recurrence for the a space. a for will monitoring monitor test in LCD monitor in the potentially also organ to for immune for foundation therapy In peer-review technology. to seen only digital with of cycle test progression than a pathway a strategic future not the of transplant earlier be draw blood The coverage Excitingly, and company can in imaging. a tells monitor for in growing assay monitoring ownership selecting only second validation a organs. able Medicare test it Medicare expand will publications a to of allograft $X first transplant Medicare the Chronix and also the that currently Oncocyte build Centers for deliver us molecular rejection market. addition, detect technologies. we as acquisition as on mode issued projected testing help us by offer is monitoring monitoring, monitoring eligible billion immune Palmetto, believe Chronix or a test imaging that results From timely or CNI an rejection of rejection, coverage organ be distinct for recurrence. recognizing
to per $X,XXX assuming translate current frame, transplant estimate price a transplanted, three-year $XX,XXX of between promo could to two- are the a test, the patient revenues on policy over $XX,XXX to followed. we total monitoring depending time which establishes addition, $X,XXX In organ per guidelines to
test partners of technology transplant for application. the tumor-derived While recurrence, of may technology super-sensitive detect in business. ultimately monitor use to there's of development and We of a we transplant to field, explore potential blood cancer continuum DetermaMX cancer-related TheraSure in use interest assay be long-term complete licensing for underlying to will in to opportunity an Oncocyte's our believe the the the monitor DNA which will for become core the
Although services and our coming made reduced pharma quarter-over-quarter. to revenue a be makes ability did our times, And fourth LCD we with improve attributes sample oncology, related double the in pipeline turnaround can sensitivity, run, from know kit along diagnostic we contracted while lumpy monitoring pharma growing the report including the pharma these business, asset and partners, project were -- this our we technology, and this importantly, streams attractive and to pharma currently projects. growth use, players traditionally, engine, focus cost for greater have like services of services our test that highly per the democratize transplant of and market. key in transplant I'd lines And solid revenues delivery enthusiastically this to most time a to finally, to to directly
agreements with the in-house molecular trial we're was companies. this And two which team proprietary Another pharma monitoring noteworthy platform developed by a from of indication. largest for specifically study of Nashville resistance thrilled blood-based company the cycle the announce for test, pharma cell partner's this accomplishment pharma It's large in XX trial. top our was our in using QX major by very in our III services a finally, assay project initiation Phase to a first using
large in and will on validation these with their engine will client lumpy systems. in leaders with pharma services pharma traditionally to to the integration look we when two the work strategic partners. growing provides forward the system experienced on services immediate more of course, progress help And two to agreements focus revenue PCR come, QX, late ramp and quarterly or respective out these begin and but projects bear in of base next-gen building smooth to sequencing fruit selected global business. tests and two revenue clinical These an there's closely growing working Our
will future our for well, As companies for channel development ex development provide global our relationships tests potentially well sales and a of platform these strategic with as as our distribution support and kit operations partner U.S.
I opportunity As important all we're to areas, are And over opportunity platform our It to XXXX, I in with Levine for to of position. three rest but the the to this to fastest-growing positions attention providers. molecular beginning some year we and financials. call making and and strengthen market of great a leading thanks of turn product oncology. We're DetermaCNI. look like total takes in these a have develop on cancer, proprietary biopharma out market of least the DetermaTX rising diagnostic Mitch? launches: envision platform great revenues DetermaIO, molecular team. time have our and in global These point, over we products review progress an with areas our diagnostic to comprehensive billion, a tool bullish large to partners $XX attract I'd incredibly of the dedicated to contracts pharmaceutical, companies At Mitch at complete
